MedPath

Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10

Not Applicable
Completed
Conditions
Ketamine-Induced Neurotoxicity
Interventions
Registration Number
NCT05648526
Lead Sponsor
Universitas Sumatera Utara
Brief Summary

The compound ACTH4-10Pro8-Gly9-Pro10 is a synthetic analog molecule of an adrenocorticotropic hormone (ACTH) short fragment. That is free from hormonal effects and has neuromodulatory effects. We investigate the neuroprotective effects of ACTH4-10Pro8-Gly9-Pro10 can lessen neurotoxicity against ketamine in neonatal rats by looking at BDNF expression in the cortex and hippocampus tissue as well as BDNF blood levels.

Detailed Description

The compound ACTH4-10Pro8-Gly9-Pro10 is a synthetic analog molecule of a short fragment of adrenocorticotropic hormone (ACTH). It is free from hormonal effects and has neuromodulatory effects. The immune-modulating and neurotrophic activity of the drug were shown to balance the state of anti-inflammatory and trophic factors (IL-IO, TNF-a, TGF-Pl, BDNF, NGF) over proinflammatory factors (IL-Ip, IL-8, CRP, LE) to increase the anti-apoptotic defense (Bcl-2 elevation), as well as to reduce the peroxidation process (increased SOD activity).

ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis. Based on research by Gusev and Skvortsova, ischemic stroke patients who were given ACTH4-10Pro8-Gly9-Pro10 showed increased levels of BDNF, decreased mortality, and reduced length of stay. Based on the description above, the researcher was interested in analyzing the effect of the administration of ACTH4-10Pro8-Gly9-Pro10 on ketamine neurotoxicity in neonatal rats by assessing the level of BDNF.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
42
Inclusion Criteria
  • Rattus norvegicus rats
  • Male, seven days old, weighing 15-20 grams
  • Spraque-Dawley strain, obtained from the Experimental Animal Care Unit
Exclusion Criteria
  • Animals that behave aggressively in observation by attacking other groups

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ACTH4-10PRO8-GLY9-PRO10ACTH4-10Pro8-Gly9-Pro10The compound ACTH4-10Pro8-Gly9-Pro10 is a synthetic analog molecule of a short fragment of adrenocorticotropic hormone (ACTH). It is free from hormonal effects and has neuromodulatory effects.
ketamine 40 mg/kg BW subcutaneouslyKetamineketamine results in impaired brain function associated with neuroapoptosis injury in the immature brain.
Primary Outcome Measures
NameTimeMethod
BDNF ExpressionOn 6 hours after the study drug dose

a protein that, in humans, is encoded by the BDNF gene

BDNF Serum ConcentrationsOn 6 hours after the study drug dose

a protein that, in humans, is encoded by the BDNF gene

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Faculty of Medicine Universitas Sumatera Utara

🇮🇩

Medan, Sumatera Utara, Indonesia

© Copyright 2025. All Rights Reserved by MedPath